Last reviewed · How we verify
(S)-Flunoxaprofen (FLUNOXAPROFEN)
(S)-Flunoxaprofen (generic name: FLUNOXAPROFEN) is a flunoxaprofen drug. It is currently in Phase 2 development for Rheumatoid arthritis.
Flunoxaprofen is thought to work by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.
Flunoxaprofen is a small molecule drug in the flunoxaprofen class, originally developed by an unknown entity and currently owned by an unknown entity. It is used to treat rheumatoid arthritis, but its exact mechanism of action is unknown. The commercial status of flunoxaprofen is unclear, as it is unknown whether it is patented or available as a generic medication. Further research is needed to determine its key safety considerations and pharmacokinetic properties. As a result, its use should be approached with caution.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FLUNOXAPROFEN |
|---|---|
| Drug class | flunoxaprofen |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's pain and inflammation response like a fire. Prostaglandins are like the fuel that keeps the fire burning. Flunoxaprofen is thought to work by reducing the amount of fuel available, thereby reducing the pain and inflammation.
Approved indications
- Rheumatoid arthritis
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (S)-Flunoxaprofen CI brief — competitive landscape report
- (S)-Flunoxaprofen updates RSS · CI watch RSS
Frequently asked questions about (S)-Flunoxaprofen
What is (S)-Flunoxaprofen?
How does (S)-Flunoxaprofen work?
What is (S)-Flunoxaprofen used for?
What is the generic name of (S)-Flunoxaprofen?
What drug class is (S)-Flunoxaprofen in?
What development phase is (S)-Flunoxaprofen in?
Related
- Drug class: All flunoxaprofen drugs
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing